FDA- Healthy People Co. Dietary Supplements: Recall - Undeclared Drug Ingredient: Recalled products pose significant... http://t.co/P4z4lbdI
Tuesday, 07 February 2012
The requested URL was not found on this server.
FDA- Healthy People Co. Dietary Supplements: Recall - Undeclared Drug Ingredient: Recalled products pose significant... http://t.co/P4z4lbdI
European Medicines Agency-Committee for Advanced Therapies stakeholders workshop, European Medicines Agency, London,... http://t.co/MP5lCokC
Committee for Advanced Therapies-European Society for Gene and Cell Therapy satellite workshop - Advanced-therapy... http://t.co/k1k475Bd
European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations... http://t.co/vzDaXLVt
DMA- Fewer organisations need a section 39 authorisation for retail sale of medical gases: In future, an... http://t.co/lfaJc3Ws
FDA- Gris-PEG (griseofulvin ultramicrosize): Health Advisory - Risk of Product Mix-Up: During packaging and... http://t.co/iZF6x02i
FDA- Acetylcysteine Solution, USP (Roxane Laboratories, Inc.): Recall - Visible Glass Particle: Use of an inhaled... http://t.co/s2pZklsh
World #Cancer Day: 4 February 2012: http://t.co/mcdk79av
Better protection of public health: EMA counts down to introduction of new pharmacovigilance legislation http://t.co/r04Drjwl
European Medicines Agency and European Food Safety Authority commit to greater co-operation: http://t.co/UDxH9iVW
Public consultation open on concept paper on #pharmacogenomics in evaluation of authorised medicines: http://t.co/HFJulUyu
European Medicines Agency recommends approval of new medicine for #Cushing’s disease http://t.co/LCL7SZtu
EMA recommends suspension of marketing authorisations for #meprobamate-containing medicines in the EU http://t.co/E7oNGdzt
Meeting highlights from the #CHMP 16-19 January 2012 http://t.co/8A4QEZc3
Register for FDA Rare Disease Patient Advocacy Day. http://t.co/RiSXSPMm
FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer. http://t.co/q54Dq94E
FDA approves Kalydeco to treat rare form of cystic fibrosis. http://t.co/CCMJlOl9
FDA approves Erivedge to treat patients with a type of skin cancer. http://t.co/QqA2G0E0
FDA approves Inlyta to treat patients with a type of advanced kidney cancer. http://t.co/vErKV3xu
New Drug Safety Podcast for Healthcare Professionals: New risk factor for PML associated with Tysabri. http://t.co/Gymql3SR
En Espanol: Safety Communication: Update: Preliminary findings from ongoing investigations of CardioGen-82. http://t.co/PTU1In8w
© 2011 Ottosen. All rights reserved.
All site content is provided "as is" and does not represent the views of any organization
